[go: up one dir, main page]

WO2005023295A3 - Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use - Google Patents

Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use Download PDF

Info

Publication number
WO2005023295A3
WO2005023295A3 PCT/NL2004/000626 NL2004000626W WO2005023295A3 WO 2005023295 A3 WO2005023295 A3 WO 2005023295A3 NL 2004000626 W NL2004000626 W NL 2004000626W WO 2005023295 A3 WO2005023295 A3 WO 2005023295A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
peptides derived
naturally processed
immunodominant peptides
neisseria meningitidis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2004/000626
Other languages
French (fr)
Other versions
WO2005023295A2 (en
Inventor
Els Cecile Antoinette Caro Van
Jong Adrianus Petrus Joseph De
Hugo Derk Meiring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlanden Staat
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Publication of WO2005023295A2 publication Critical patent/WO2005023295A2/en
Publication of WO2005023295A3 publication Critical patent/WO2005023295A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to precisely identified naturally processed immunodominant peptides derived from N. meningitidis serotype B, that may be used in ex vivo diagnosis of human MHC class II restricted immune responses to meningococcal antigens. The naturally presented immunodominant peptides are highly immunogenic in vivo and are capable of recalling an antigen specific CD4+T cell response ex vivo. The immunodominant PorA-derived peptides may further be used in methods for vaccination against N. meningitidis serotype B.
PCT/NL2004/000626 2003-09-10 2004-09-10 Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use Ceased WO2005023295A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03077849 2003-09-10
EP03077849.2 2003-09-10

Publications (2)

Publication Number Publication Date
WO2005023295A2 WO2005023295A2 (en) 2005-03-17
WO2005023295A3 true WO2005023295A3 (en) 2005-09-29

Family

ID=34259181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2004/000626 Ceased WO2005023295A2 (en) 2003-09-10 2004-09-10 Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use

Country Status (1)

Country Link
WO (1) WO2005023295A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1943269A2 (en) * 2005-10-14 2008-07-16 Intercell AG Neisseria meningitidis antigens
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0849275A1 (en) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylated peptides
WO2000003003A2 (en) * 1998-07-10 2000-01-20 The University Of Nottingham Screening of neisserial vaccine candidates and vaccines against pathogenic neisseria
WO2002083711A2 (en) * 2001-04-17 2002-10-24 Chiron Corporation Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
EP1288292A1 (en) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Long peptides of 22-40 amino acid residues that induce and/or enhance antigen specific immune responses.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0849275A1 (en) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylated peptides
WO2000003003A2 (en) * 1998-07-10 2000-01-20 The University Of Nottingham Screening of neisserial vaccine candidates and vaccines against pathogenic neisseria
WO2002083711A2 (en) * 2001-04-17 2002-10-24 Chiron Corporation Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
EP1288292A1 (en) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Long peptides of 22-40 amino acid residues that induce and/or enhance antigen specific immune responses.

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DELVIG A.A. ET AL.: "T-cell epitope mapping the PorB protein of serogroup B Neisseria meningitidis in B10 congenic strains of mice.", CLIN. IMMUN. IMMUNOPATH., vol. 85, no. 2, November 1997 (1997-11-01), pages 134 - 142, XP002266485 *
DERRICK J.P. ET AL.: "Structural and evolutionary inference from molecular variation in Neisseria porins.", INFECT. IMMUN., vol. 67, no. 5, May 1999 (1999-05-01), pages 2406 - 2413, XP002266483 *
VAN DER LEY P. ET AL.: "Topology of outer membrane porins in pathogenic Neisseria Spp..", INFECT. IMMUN., vol. 59, no. 9, September 1991 (1991-09-01), pages 2963 - 2971, XP000946494 *
VERMONT C. ET AL.: "Neisseria meningitidis serogroup B : laboratory correlates of protection.", FEMS IMMUN. MED. MICROB., vol. 34, 2002, pages 89 - 96, XP002266484 *
WIERTZ E.J.H.J. ET AL.: "Identification of T cell epitopes occuring in a meningococcal class 1 outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis.", J. EXP. MED., vol. 176, July 1992 (1992-07-01), pages 79 - 88, XP002266481 *
WIERTZ E.J.H.J. ET AL.: "Identification of T cell epitopes with selected synthetic peptides and determination of HLA restriction elements.", J. IMMUNOL., vol. 147, no. 6, 15 September 1991 (1991-09-15), pages 2012 - 2018, XP000986185 *
WIERTZ E.J.H.J. ET AL.: "T-cell responses to outer membrane proteins of Neisseria meningitidis : Comparative study of the Opa, Opc, and PorA proteins.", INFECT. IMMUN., vol. 64, no. 1, January 1996 (1996-01-01), pages 298 - 304, XP002127427 *

Also Published As

Publication number Publication date
WO2005023295A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
Dietrich et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity
EP2181714A3 (en) Immunogenic composition for use in vaccination against staphylococcei
RU2378009C2 (en) Protein immunisation against meningococci of serogroup y
CR10123A (en) VACCINE.
TW200722101A (en) Novel composition
EP1897555A3 (en) Supplemented OMV vaccine against meningococcus
MX348734B (en) Multiple vaccination including serogroup c meningococcus.
WO2005037190A3 (en) Multiplex vaccines
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
WO2008112344A3 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
UA99659C2 (en) Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
HRP20120433T1 (en) Meningococcal vaccine formulations
WO2004089299A3 (en) Pulsatile transdermally administered antigens and adjuvants
GB2434367A (en) Improved vaccines
EP2302033A3 (en) Identification of virulence associated regions RD1 and RD5 enabling the development of improved vaccines of M. bovis BCG and M. microti
Reed et al. Vaccines for parasitic and bacterial diseases
WO2007016185A3 (en) Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
Stuart et al. Cassette-based presentation of SIV epitopes with recombinant gas vesicles from halophilic archaea
EP1852125A3 (en) Neisserial vaccine compositions and methods
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
WO2021247715A3 (en) Immunogenic francisella antigens and their use in immunization of fish against francisellosis
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
MX2023009728A (en) Meningococcal b recombinant vaccine.
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
WO2005007804A3 (en) Anthrax conjugate vaccine and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase